Lifesci Capital Equities Analysts Raise Earnings Estimates for Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – Research analysts at Lifesci Capital upped their Q3 2024 EPS estimates for shares of Enliven Therapeutics in a note issued to investors on Wednesday, August 14th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings of ($0.55) per share for the quarter, up from their previous forecast of ($0.56). The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($2.26) per share. Lifesci Capital also issued estimates for Enliven Therapeutics’ Q4 2024 earnings at ($0.57) EPS, FY2024 earnings at ($2.08) EPS and FY2025 earnings at ($2.64) EPS.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17.

Several other research analysts have also commented on the stock. Robert W. Baird assumed coverage on shares of Enliven Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price target on the stock. Baird R W raised shares of Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th.

Enliven Therapeutics Price Performance

NASDAQ ELVN opened at $23.71 on Friday. Enliven Therapeutics has a 1-year low of $9.80 and a 1-year high of $27.67. The firm has a market capitalization of $1.12 billion, a P/E ratio of -12.28 and a beta of 1.10. The business’s 50-day simple moving average is $22.90 and its 200-day simple moving average is $20.12.

Insiders Place Their Bets

In other news, CEO Samuel Kintz sold 12,000 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $23.18, for a total value of $278,160.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Richard A. Heyman sold 1,702 shares of Enliven Therapeutics stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $27.51, for a total transaction of $46,822.02. Following the sale, the director now owns 131,643 shares of the company’s stock, valued at approximately $3,621,498.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Samuel Kintz sold 12,000 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $23.18, for a total transaction of $278,160.00. The disclosure for this sale can be found here. Insiders have sold a total of 123,668 shares of company stock worth $3,057,633 over the last quarter. 29.20% of the stock is owned by corporate insiders.

Institutional Trading of Enliven Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. First Turn Management LLC purchased a new position in Enliven Therapeutics in the second quarter valued at about $9,657,000. Janus Henderson Group PLC boosted its stake in shares of Enliven Therapeutics by 74.8% during the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after buying an additional 305,397 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Enliven Therapeutics during the second quarter worth approximately $4,489,000. Baker BROS. Advisors LP bought a new stake in shares of Enliven Therapeutics in the first quarter worth $2,020,000. Finally, Nicholas Investment Partners LP acquired a new stake in Enliven Therapeutics in the second quarter valued at $1,310,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.